The Short Bowel Syndrome Market Is Estimated To Witness High Growth Owing To Growing Awareness Programs
The Short Bowel Syndrome Market is estimated to be valued at US$ 188.9 Bn in 2023 and is expected to exhibit a CAGR of 11.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Short bowel syndrome is a malabsorption disorder that occurs when the small intestine does not work properly or a large part of it has been removed by surgery. Removal of part of the small intestine leads to insufficient absorption of nutrients, vitamins, minerals, and fluid from food. The main symptoms include diarrhea, dehydration, weight loss, malnutrition, and weakening of bones. The condition is commonly seen in people who have undergone extensive bowel resection surgeries for various reasons like Crohn’s disease, mesenteric ischemia, and tumors.
Market Dynamics:
The short bowel syndrome market is expected to witness significant growth over the forecast period owing to growing awareness programs and increasing research funding and partnerships. Several non-profit patient advocacy organizations conduct programs and activities to spread awareness about short bowel syndrome, its diagnosis, management and treatment options. For instance, The American Short Bowel Syndrome Association organizes conferences, resources and counselling sessions to educate patients and caregivers. Further, rising research funding from government as well as private sources to develop innovative therapies is also fueling market growth. Growing partnerships between pharmaceutical companies, research institutes and patient advocacy organizations is encouraging new drug development. Additionally, increasing number of clinical trials evaluating the effectiveness of various treatment modalities including combination therapies, novel drugs and gut microbiota transplantation is stimulating market expansion. However, high cost of immunotherapy treatment and side effects of immunotherapy drugs may hamper market growth over the forecast period.
Segment Analysis
The global short bowel syndrome market can be segmented based on drug class, end user and region. Based on drug class, the market is segmented into anti-diarrheal, glutamine analogs, growth hormone, short bowel syndrome drugs, and teduglutide. The glutamine analogs segment currently dominates the market owing to the effectiveness of these drugs in treating patients with short bowel syndrome.
PEST Analysis
Political: The governments across various countries are increasing their funding for research and development activities focused on developing new and improved treatment options for short bowel syndrome.
Economic: The rising per capita healthcare expenditures and growing awareness about short bowel syndrome treatment are fueling the growth of the global market.
Social: The increasing prevalence of short bowel syndrome due to various medical conditions and high demand for effective management are boosting the adoption of drugs and other therapies.
Technological: Advancements in drug delivery systems and development of novel therapeutic molecules are encouraging pharmaceutical companies to invest in this market.
Key Takeaways
The Global Short Bowel Syndrome Market Growth is expected to witness high, exhibiting a CAGR of 11.5% over the forecast period due to increasing research funding and growing adoption of nutritional therapies. The North America region currently dominates the market due to rising healthcare expenditures and strong presence of key players in the region.
Regional analysis
The North America region currently dominates the global market for short bowel syndrome due to growing research funding by governments and presence of advanced healthcare facilities in countries like the US and Canada. Asia Pacific is projected to witness the fastest growth during the forecast period owing to rising cases of short bowel syndrome, increasing healthcare investments, and growing awareness regarding disease treatments.
Key players
The key players operating in the short bowel syndrome market are Zealand Pharma, Ardelyx Inc., Emmaus Life Sciences, GLyPharma Therapeutic Inc., OxThera, Shire, Sancilio & Company Inc., Naia Pharmaceuticals. Key players are focusing on developing novel therapies to expand their product portfolio.